Regulus Therapeutics Inc expected to post a loss of 7  cents a share - Earnings Preview

Regulus Therapeutics

08/03/2022 22:51

* Regulus Therapeutics Inc  RGLS.OQ   RGLS.O  is expected
to show
a fall in quarterly revenue when it reports  results on March
10. 
    * ​Refinitiv's mean analyst estimate for Regulus
Therapeutics Inc
is for a loss of 7 cents per share. For the same quarter last
year, the company reported a loss of 3 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $2​, above​ its last closing price of $0.29.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.08       -0.08      -0.10     Missed  -29
 Jun. 30 2021  -0.08       -0.08      -0.08     Met     0
 Mar. 31 2021  -0.09       -0.09      -0.08     Beat    11.1​
 Dec. 31 2020  -0.10       -0.14      -0.03     Beat    78.6
 ​​Sep.        -0.22       -0.21      -0.04     Beat    80.7
 30 2020                                                
 Jun. 30 2020  -0.08       -0.11      -0.23     Missed  -114​
 Mar. 31 2020  -0.16       -0.12      -0.25     Missed  -108.3
 Dec. 31 2019  -0.23       -0.24      -0.23     Beat    4.2
 This summary was machine generated March 8 at 22:51 GMT.  All
figures in US dollars  unless otherwise stated